胃癌CIK细胞治疗的研究现状及进展

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (572 KB)
输出: BibTeX | EndNote (RIS)

摘要近年来,随着生物技术的迅猛发展,生物治疗在提高手术、放化疗疗效以及延长患者生存期、改善生活质量等方面已经受到越来越多的关注^[1]。由细胞因子诱导的杀伤细胞(cytokine-inducedkillercells,CIK)作为一类新型的抗肿瘤效应细胞,可直接杀伤肿瘤细胞,并可调节和增强机体的免疫功能,是继淋巴因子激活的杀伤细胞(LAK)、细胞毒T淋巴细胞(CTL)、肿瘤浸润淋巴细胞(TIL)后出现的一类更为有效的杀瘤效应细胞^[2]。目前,CIK细胞已应用于多种肿瘤的治疗^[1,2],并在胃癌治疗中积累了一定经验,笔者就CIK细胞的生物学特征、抗肿瘤机制及在胃癌临床治疗上的应用及进展做一综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：胃癌, CIK细胞, 应用

收稿日期: 2013-07-02

ZTFLH:

R735.2

基金资助:

河北省科技支撑计划项目(130202)

通讯作者: 汪治宇,E-mail:drwangzhiyu@hotmail.com E-mail: sx1_perfect@yahoo.cn

作者简介: 舒心,硕士研究生,医师,E-mail:sx1_perfect@yahoo.cn

引用本文:

舒心,李幸综述汪治宇审校. 胃癌CIK细胞治疗的研究现状及进展[J]. 武警医学, 2013, 24(6): 526-528.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2013/V24/I6/526

[1]	Jiang J, Shen Y, Wu C, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J]. World J Gastroenterol 2010 ,16(48): 6155-6162.
[1]	Jiang J, Shen Y, Wu C, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J]. World J Gastroenterol 2010 ,16(48): 6155-6162.
[2]	Wu C, Jiang J, Shi L,et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer[J].Anticancer Res, 2008,28: 3997-4002.
[2]	Wu C, Jiang J, Shi L,et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer[J].Anticancer Res, 2008,28: 3997-4002.
[3]	Hoffman D M,Gitlitz B J,Belldegrun A,et al.Adoptive cellular therapy[J].Semin Oncol,2000,27(2):221-233.
[4]	Yeon Jin Kim, Jaeseung Lim, Jong Soon Kang,et al.Adoptive Immunotherapy of Human Gastric Cancer with Ex Vivo Expanded T Cells[J].Arch Pharm Res,2010, 33(11):1789-1795.
[3]	Hoffman D M,Gitlitz B J,Belldegrun A,et al.Adoptive cellular therapy[J].Semin Oncol,2000,27(2):221-233.
[5]	Takayama T, Sekine T, Makuuchi M,et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet,2000,356,802-807.
[4]	Yeon Jin Kim, Jaeseung Lim, Jong Soon Kang,et al.Adoptive Immunotherapy of Human Gastric Cancer with Ex Vivo Expanded T Cells[J].Arch Pharm Res,2010, 33(11):1789-1795.
[6]	Schmidt-Wolf I G,Lefterova P,Mehta B A,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Exp Hematol,1993,21:1673-1679.
[7]	Schrmitz M,Zhao S,Deuse Y,et al.Tumorcidal potential of native blood dendritic cells:direct tumor cell killing and activation of NK cell-mediated cytotoxicity[J].J Immunol,2005,174(7):4127-4134.
[5]	Takayama T, Sekine T, Makuuchi M,et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet,2000,356,802-807.
[8]	Bela A Mehta,Schmidt-Wolf IGH,Weissman I L,et al.Two pathways of exocytosis of cytoplasmic granule cotents and target cell killing by cytokine-iuduced CD3+CD56+killer cells[J].Blood,1995,86:3493-3499.
[9]	Brinkmann O A, Bruns F, Gosheger G, et al. Treatment of bone metastases and local recurrence from renal cell carcinoma with immuno chemotherapy and radiation[J]. World J Urol,2005,23(3):185-190.
[6]	Schmidt-Wolf I G,Lefterova P,Mehta B A,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Exp Hematol,1993,21:1673-1679.
[10]	Verneris M R, Kornacker M, Mailander V, et al. Resistance ofex vi-vo expanded CD3+ CD56+T cells to Fas-mediated apoptosis[ J]. Cancer Immunol Immunother, 2000, 49 (6):335-345.
[7]	Schrmitz M,Zhao S,Deuse Y,et al.Tumorcidal potential of native blood dendritic cells:direct tumor cell killing and activation of NK cell-mediated cytotoxicity[J].J Immunol,2005,174(7):4127-4134.
[11]	孙抒,李雪梅,王建光,等.CIK细胞对MGC-803胃癌细胞株抗增殖及诱导凋亡作用的研究[J].中国免疫学杂志,2004,20(12):831-837.
[8]	Bela A Mehta,Schmidt-Wolf IGH,Weissman I L,et al.Two pathways of exocytosis of cytoplasmic granule cotents and target cell killing by cytokine-iuduced CD3+CD56+killer cells[J].Blood,1995,86:3493-3499.
[12]	Parkin D M,Bray F,Ferlay J,et al.Global cancer statistics,2002[J]. CA Cancer J Clin,2005,55(2):74-108.
[9]	Brinkmann O A, Bruns F, Gosheger G, et al. Treatment of bone metastases and local recurrence from renal cell carcinoma with immuno chemotherapy and radiation[J]. World J Urol,2005,23(3):185-190.
[13]	Chen L, Tian H, Chen J, et al.Surgical management of gastric stump cancer: a report of 37cases[J]. J Zhejiang Univ Sci B, 2005,6:38-42.
[10]	Verneris M R, Kornacker M, Mailander V, et al. Resistance ofex vi-vo expanded CD3+ CD56+T cells to Fas-mediated apoptosis[ J]. Cancer Immunol Immunother, 2000, 49 (6):335-345.
[11]	孙抒,李雪梅,王建光,等.CIK细胞对MGC-803胃癌细胞株抗增殖及诱导凋亡作用的研究[J].中国免疫学杂志,2004,20(12):831-837.
[14]	Lin W L, Li D G, Chen Q, et al. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma[J].World J Gastroenterol, 2004,10: 2911-2915.
[12]	Parkin D M,Bray F,Ferlay J,et al.Global cancer statistics,2002[J]. CA Cancer J Clin,2005,55(2):74-108.
[15]	Schmidt-Wolf IGH, Negrin R S, Kiem H, et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity [J]. J Exp Med,1991,174:139-149.
[13]	Chen L, Tian H, Chen J, et al.Surgical management of gastric stump cancer: a report of 37cases[J]. J Zhejiang Univ Sci B, 2005,6:38-42.
[16]	Yamaguchi K, Shimamura T, Hyodo I, et al.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer[J]. Br J Cancer,2006,94:1803-1808.
[14]	Lin W L, Li D G, Chen Q, et al. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma[J].World J Gastroenterol, 2004,10: 2911-2915.
[17]	Margolin K A, Negrin R S, Wong K K,et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy[J]. Immunol Rev,1997,157: 231-240.
[18]	樊永丽,赵华,于津浦,等. 胃癌患者术后化疗联合CIK免疫治疗的临床疗效[J].中国肿瘤生物治疗杂志,2012,19(2):168-174.
[15]	Schmidt-Wolf IGH, Negrin R S, Kiem H, et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity [J]. J Exp Med,1991,174:139-149.
[19]	Kim Y J,Lim J,Kang J S,et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells [J].Arch Pharm Res,2010,33( 11) : 1789-1795.
[16]	Yamaguchi K, Shimamura T, Hyodo I, et al.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer[J]. Br J Cancer,2006,94:1803-1808.
[17]	Margolin K A, Negrin R S, Wong K K,et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy[J]. Immunol Rev,1997,157: 231-240.
[18]	樊永丽,赵华,于津浦,等. 胃癌患者术后化疗联合CIK免疫治疗的临床疗效[J].中国肿瘤生物治疗杂志,2012,19(2):168-174.
[20]	杨光,王彬,何志杰,等.自体CIK细胞治疗晚期恶性肿瘤的临床研究[J].南京医科大学学报﹙自然科学版﹚,2009,29(12):1744-1747.
[21]	蒋敬庭,吴昌平,Ning Xu,等.CIK细胞治疗老年人中晚期胃癌的副反应分析[J].肿瘤,2006,26(10):950-952.
[19]	Kim Y J,Lim J,Kang J S,et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells [J].Arch Pharm Res,2010,33( 11) : 1789-1795.
[22]	Brinkmann O A,Bruns F,Gosheger G,et al.Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation[J].World J Urol,2005,23(3):185-190.
[23]	Jiang J, Xu N, Wu C, et al.Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. AnticancerRes, 2006, 26: 2237-2242.
[24]	张彤,任国平,张蕊.紫杉醇、奥沙利铂、氟尿嘧啶方案联合自体CIK细胞输注治疗Ⅳ期胃癌的疗效与安全性研究[J].中国临床实践,2012,15(7):2418-2410.
[20]	杨光,王彬,何志杰,等.自体CIK细胞治疗晚期恶性肿瘤的临床研究[J].南京医科大学学报﹙自然科学版﹚,2009,29(12):1744-1747.
[21]	蒋敬庭,吴昌平,Ning Xu,等.CIK细胞治疗老年人中晚期胃癌的副反应分析[J].肿瘤,2006,26(10):950-952.
[25]	Thome S H,Negrin R S,Contag C H.Synergistic antitumor effects of immune cell—viral biotherapy[J].Science,2006,3(1l):17802-17841.
[22]	Brinkmann O A,Bruns F,Gosheger G,et al.Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation[J].World J Urol,2005,23(3):185-190.
[23]	Jiang J, Xu N, Wu C, et al.Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. AnticancerRes, 2006, 26: 2237-2242.
[26]	Liu K,Caldwell S A,Greenetlch K M,et al.CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape[J]. J Immunol,2006,176(6):3374-3382.
[24]	张彤,任国平,张蕊.紫杉醇、奥沙利铂、氟尿嘧啶方案联合自体CIK细胞输注治疗Ⅳ期胃癌的疗效与安全性研究[J].中国临床实践,2012,15(7):2418-2410.
[27]	Ramakrishnan R, As sudaniD, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility toCTL-mediated killing during cancer immunotherapy in mice [ J]. J Clin Invest, 2010,120(4):1111-1124.
[25]	Thome S H,Negrin R S,Contag C H.Synergistic antitumor effects of immune cell—viral biotherapy[J].Science,2006,3(1l):17802-17841.
[28]	李辉,毛伟征,安岗,等.细胞因子诱导杀伤细胞杀伤胃癌的特异性与非特异性研究[J].中华实验外科杂志,2012,27(4):428-430.
[26]	Liu K,Caldwell S A,Greenetlch K M,et al.CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape[J]. J Immunol,2006,176(6):3374-3382.
[29]	Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy[J]. Oncologist, 2002, 7 Suppl 4: 2-8.
[30]	张林,侯艳红,段云卉.EGFR单抗联合CIK细胞治疗胃癌的实验研究[J].胃肠病学,2010,15(11):657-660.
[27]	Ramakrishnan R, As sudaniD, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility toCTL-mediated killing during cancer immunotherapy in mice [ J]. J Clin Invest, 2010,120(4):1111-1124.
[28]	李辉,毛伟征,安岗,等.细胞因子诱导杀伤细胞杀伤胃癌的特异性与非特异性研究[J].中华实验外科杂志,2012,27(4):428-430.
[29]	Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy[J]. Oncologist, 2002, 7 Suppl 4: 2-8.
[30]	张林,侯艳红,段云卉.EGFR单抗联合CIK细胞治疗胃癌的实验研究[J].胃肠病学,2010,15(11):657-660.